Opko Health’s stock price movements
On November 9, Opko Health (OPK) closed at $3.09, which was 11.46% lower than its previous closing price. The stock was trading 15.57% lower than its closing price of $3.66 on November 1. To know more about the major events that had a significant impact on Opko Health’s stock price, read Why Opko Health Rose 15% Yesterday.
Opko Health reported its third-quarter earnings on November 9. In the third quarter, Opko Health reported revenues of $249.81 million, which is a YoY rise of 1.53%. The company reported a net loss of $27.65 million, a YoY improvement of 8.3 million.
According to the company’s third-quarter earnings conference call, Opko Health’s BioReference Laboratories (or BRL), which is the third largest reference laboratory in the US, has been one of the major revenue drivers for the company in 2018. In the third quarter, revenue from services, or BRL revenues, accounted for 81.18% of Opko Health’s total revenues.
Based on its closing price on November 9, the company has returned -18.04% in the last week, -12.71% in the last month, and -45.02% in the last quarter. Opko Health gave returns of -4.04% in the last half year, -52.97% in the last year, and -36.94% YTD.
Analysts’ recommendations and target price for Opko Health
The 12-month consensus analyst recommendation for Opko Health on November 10 is a “buy.” The 12-month consensus target price for the company is $12.63, which is 308.74% higher than its last closing price on November 9. The highest target price estimate for the company is $20, and the lowest target price estimate is $4.5.
Out of the five analysts covering Opko Health on November 9, one analyst has rated the company as a “strong buy,” two analysts have rated the company as a “buy,” one analyst has rated the company as a “hold,” and one analyst has rated the company as a “sell.”
In the next article, we’ll discuss revenue projections for Opko Health for fiscal 2018.